IGX — Intelgenx Technologies Share News
0.000.00%
Last trade - 00:00- CA$41.92m
- CA$62.83m
- $1.04m
Brief: IntelGenx Announces Collaboration With UPEI To Evaluate Acceptance And Preference Of VetaFilm Platform In Dogs And Cats
Brief: Intelgenx Technologies Receives FDA PDUFA Date For Rizafilm®
Brief: Intelgenx Reschedules Third Quarter 2022 Conference Call Due To Technical Issues Experienced Today By Webcast Vendor
Brief: Intelgenx Reports Third Quarter 2022 Financial Results
Brief: Intelgenx Enters In Agreement For Cbd-Infused Vetafilm
Brief: Intelgenx Files Provisional U.S. Patent Application For Advanced Oral Film Formulation Improving Cannabinoid Onset Of Action
Brief: Intelgenx Receives FDA GDUFA Date For Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
Brief: Intelgenx Announces Issuance Of New U.S. Patent Covering Versafilm Technology
Brief: Intelgenx Submits Response To Crl From FDA For Rizaport® Versafilm®
Brief: Intelgenx Announces Enrollment Reaches Halfway Mark In ‘Buena’ Montelukast Versafilm® Phase 2A Clinical Trial In Patients With Mild To Moderate Alzheimer’S Disease
Brief: Intelgenx Reports Second Quarter 2022 Financial Results
Brief: Intelgenx Technologies Reports Q1 Loss Per Share $0.02
Brief: Intelgenx Reports Fourth Quarter And Full-Year 2021 Financial Results
Brief: Intelgenx Receives Third Loan Tranche From ATAI
Brief: First Patient Dosed In Intelgenx's Resumed 'Buena' Montelukast Versafilm® Phase 2A Trial In Patients With Alzheimer's Disease
Brief: Intelgenx Initiates Arbitration Proceeding Against Tilray Related To An Alleged Breach Of Worldwide Cannabis-Infused Versafilm Agreement
Brief: Intelgenx Reports Third Quarter 2021 Financial Results
Brief: Intelgenx Receives Final Approval To Graduate To Toronto Stock Exchange
Brief: Aquestive Therapeutics And Intelgenx Partner With Leading Men's Health Company To Market Tadalafil Oral Films In U.S.